Abstract Submission Guidelines
*Extended* Abstract Deadline: June 15, 2020 @ 11:59PM, Eastern Daylight Time (EDT)
Late-Breaking Abstracts: September 4, 2020 - submitted exclusively via email to firstname.lastname@example.org.
* Please note that the Late-Breaking Abstract submission is solely for abstracts with late-breaking data and not for abstracts submitted “late.” Any “late” abstracts will be rejected outright. In order to fulfil the criteria for a late-breaking abstract you must enter the reasons why your abstract is a late-breaking abstract. Failure to do so, will mean that the abstract will not be reviewed. Submit your Late-Breaking Abstract at email@example.com.
All accepted abstracts will be published on SIU Academy in ePoster format and in the inaugural issue of the Société Internationale d’Urologie Journal as a digital supplement.
Abstracts are no longer published in World Journal of Urology.
1. Submission Categories and Educational Objectives
The 2020 Congress Learning Objectives are as follows:
After this educational event, attendees should be able to:
- Determine diagnosis and management of basic and complicated urological infections
- Describe the role of eHealth, new diagnostic methods and delivery of urological education and care in the developing world
- Summarize recent advances in molecular markers for urological diseases
- Report the application of therapeutic modalities and management of complex stone disease
- Discuss multimodal approach to treatment of urological cancers
- List recent advances in minimally invasive surgery
- Describe the current management of lower urinary tract symptoms
- Identify methods of dissemination of knowledge and care to underserved areas
2. Rules for Authors
Prior Publication of Material
The SIU Congress is a forum for the presentation of novel research findings. The work covered by the abstract must not have been published (manuscript or abstract) before October 7, 2020. If the work has been presented at another meeting, the author must disclose when and where it was presented (during submission process), so that the Abstract Review Committee can make its decision based on all available details.
The SIU is committed to offering participants an open forum for scientific discussion, wherein all scientists and clinicians are invited to contribute actively. To preserve this valuable environment, the SIU urges all presenters to avoid statements, symbols or other displays that are subjective and unscientific in nature.
Registration and Expenses
Abstract status notifications will be sent to all submitters in late July. We ask abstract presenters to register before the early-bird registration deadline, which is August 11, 2020; after this date presenting authors who have not paid their registration fees will be excluded from the programme as well as from the Société Internationale d’Urologie Journal Abstract supplement and publication on SIU Academy. No exceptions will be granted.
Failure to Present
Should the author (or a designated co-author) of an accepted abstract fail to present the work as scheduled, subsequent abstracts submitted by the individual will be flagged to the scientific committee as coming from a prior "no-show presenter" and will be judged accordingly. This could result in the non-acceptance of future submissions at SIU meetings.
Each abstract will be blinded and scored by up to three reviewers. Abstracts will be accepted on the basis of scientific merit.
Abstracts may not be revised or resubmitted after the deadline of June 15, 2020.
Please submit abstract withdrawal requests in writing by August 11, 2020. Please note that if the request is received after this date, it may not be possible to exclude from planned publications.
Change of Presenting Author
Please submit requests in writing by August 11, 2020. After this date, changes will no longer appear in the Société Internationale d’Urologie Journal (SIUJ) Abstract Book and SIU Congress materials.
Publication and Copyright
3. Preparation of Abstracts
Abstracts must be written and presented in English. Careful typing and proofreading is essential. If accepted, the abstract will be published as submitted. Errors, misspellings, incorrect hyphenation, and deviations from the use of correct English will be glaringly apparent in the published abstract. Once the abstract is submitted, changes, corrections or rewording will not be possible. Presenters are requested to devote the necessary attention to language in order to avoid deviations from the use of good English. The Scientific Committee reserves the right to reject abstracts which are presented in poor English or to request an immediate revision.
Abstracts should not exceed 350 words. Deduct 50 words for each table or graph included (to a maximum of 1 page on US Letter, 8.5 x 11 inch paper.)
Images, Tables and Graphs
Images are not permitted, as they do not reproduce well. Brief and clear tables or graphs are accepted (maximum of 1 page on US Letter, 8.5 x 11 inch paper). If the Tables/Graphs submitted exceed 1 page, those exceeding the limit will be excluded from publication.
To ensure that your abstract receives proper scientific consideration, be sure to submit to the appropriate topic category as indicated on the web submission page.
Title of Abstract
Your abstract must have a short, specific title (no abbreviations) that indicates the nature of the investigation. Please use title case.
Abstracts MUST include the following four distinct sections:
- Introduction and Objectives
- Materials and Methods
Use generic drug names.
Standard abbreviations may be used without definition. Nonstandard abbreviations should be kept to a minimum and placed in parentheses after the first use of the word or phrase.
Do not include references, credits or grant support.
Author Names and Affiliations
List of authors: Do NOT include the authors list directly with your abstract. Only submit this information on the online authors form. There is only one presenting author permitted per submission. All authors must complete, sign and submit a Conflict of Interest disclosure form.
Spelling: If an author's name appears on more than one abstract, it must be identical on each abstract in order to ensure proper indexing.
Any human experimentation conducted as part of the submitted abstract(s) must follow the protocol approved by the institutional or local committee on ethics in human investigation; or, if no such committee exists, the investigation should have been conducted in accordance with the principles of the World Medical Association’s Helsinki Declaration. The Scientific Committee may inquire further into ethical aspects when evaluating the abstract(s).
Abstracts that describe single clinical cases, or investigations of compounds that involve inadequate numbers of study subjects, or abstracts that lack quantitative data will not be accepted. Authors should not "split" data to create several abstracts from one. If splitting is judged to have occurred, priority scores of related abstracts will be reduced.
Abstracts containing identical or nearly identical data submitted from the same institution (and/or individuals) describing the same study population will be disqualified.
Statements such as "results will be discussed" will automatically disqualify the abstract. Reviewers require specific data on which to base their evaluation.
Bear in mind that your abstract will be rated according to the following criteria:
• Is the design of the study valid?
• Are the methods appropriate?
• What is the significance of the results?
• Is the event described in the case report significant?
3-4 Educational Objectives must be submitted for each abstract.
For more information, consult: Writing Clear Learning Objectives.
Complications in Laparoscopic Transperitoneal Partial Nephrectomy
Introduction and Objectives: We review the complications of laparoscopic partial nephrectomy in a single surgeon series.
Materials and Methods: Between July 1999 and April 2006, a total of 125 patients underwent laparoscopic transperitoneal partial nephrectomy. Mean patient age was 58 years (range 33 to 87) and male to female ratio was 2:1. In 43 patients (34%) the procedure was hand-assisted. A database was kept prospectively for all patients.
Results: Mean operative time was 104 minutes (range 35 to 180) and average surgical bleeding was 258 ml (range 0 to 2000). For procedures with warm ischemia, mean arterial clamping time was 26 minutes (range 15 to 60). Mean tumor size was 2.7 cm (range 1 to 7). A total of 14 patients (11.2%) had one or more complications which were intraoperative 6 (4.8%) and postoperative 8 (6.4%) with two delayed complications. Intraoperative hemorrhage occurred in 6 cases (4.8%), and postoperatively in another 6 (4.8%). Intraoperative hemorrhage was managed in 2 cases with laparoscopic radical nephrectomy and in 4 cases with intracorporeal suture. Postoperative hemorrhage required reoperation in 4 patients: two open radical nephrectomies, one laparoscopic radical nephrectomy and one laparoscopic re-suture of the kidney. The remaining two patients were managed with endovascular (percutaneous) embolization. Urine leakage occurred in one case (0.8%) and was managed conservatively with a double-J stent. A digestive hemorrhage and a pulmonary embolism were presented by two patients (1.6%). Transfusion rate was 10.4%. No case required conversion to open surgery. Mean hospital stay was 3.6 days (range 1 to 12).
Conclusion: Laparoscopic transperitoneal partial nephrectomy is technically demanding with a high potential for complications. The most frequent complication is either intra- or post-operative hemorrhage. For delayed bleeding, endovascular techniques are safe and effective and thus our first choice in the stable patient.
4. Video Submissions
If you wish to submit a Video, please use the following link to upload your file: http://www.siu-urology.org/vimeoapi/
Please note that videos MUST be uploaded prior to the submission deadline in order to be considered for review, and also note that a video submission MUST include an abstract.
All videos must be in the final format and include the exact title, presenting author and production date in the submission title. The video itself should be blinded for review. Maximum duration of video: 7 minutes. Submitters may wish to include commentary. All audio and written commentary must be in English.
For any questions pertaining to your abstract submission, please contact: firstname.lastname@example.org.